4.6 Article

Persistent and Progressive Outer Retina Thinning in Frontotemporal Degeneration

Journal

FRONTIERS IN NEUROSCIENCE
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2019.00298

Keywords

frontotemporal degeneration; optical coherence tomography; retina; tauopathy; progressive supranuclear palsy

Categories

Funding

  1. NIH [AG017586, NS053488, AG052943, 2-P30-EY01583-26, K23NS088341, KL2TR001879]
  2. Penn Institute on Aging
  3. Research to Prevent Blindness (New York, NY, United States)
  4. Paul and Evanina Mackall Foundation Trust (Chicago, IL, United States)
  5. NATIONAL EYE INSTITUTE [P30EY001583] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Objective: While Alzheimer's disease is associated with inner retina thinning measured by spectral-domain optical coherence tomography (SD-OCT), our previous cross-sectional study suggested outer retina thinning in frontotemporal degeneration (FTD) patients compared to controls without neurodegenerative disease; we sought to evaluate longitudinal changes of this potential biomarker. Methods: SD-OCT retinal layer thicknesses were measured at baseline and after 1-2 years. Clinical criteria, genetic analysis, and a cerebrospinal fluid biomarker (total tau: (beta-amyloid) to exclude likely underlying Alzheimer's disease pathology were used to define a subgroup of predicted molecular pathology (i.e., tauopathy). Retinal layer thicknesses and rates of change in all FTD patients (n = 16 patients, 30 eyes) and the tauopathy subgroup (n = 9 patients,16 eyes) were compared to controls (n = 30 controls, 47 eyes) using a generalized linear model accounting for inter-eye correlation and adjusting for age, sex, and race. Correlations between retinal layer thicknesses and Mini-Mental State Examinations (MMSE) were assessed. Results: Compared to controls, returning FTD patients (143 vs. 130 mu m, p = 0.005) and the tauopathy subgroup (143 vs. 128 mu m, p = 0.03) had thinner outer retinas but similar inner layer thicknesses. Compared to controls, the outer retina thinning rate was not significant for all FTD patients (p = 0.34), but was significant for the tauopathy subgroup (-3.9 vs. 0.4 mu m/year, p = 0.03). Outer retina thickness change correlated with MMSE change in FTD patients (Spearman rho = 0.60, p = 0.02) and the tauopathy subgroup (rho = 0.73, p = 0.04). Conclusion: Our finding of FTD outer retina thinning persists and longitudinally correlates with disease progression. These findings were especially seen in probable tauopathy patients, which showed progressive outer retina thinning.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Clinical Neurology

Preparing for the age of therapeutic trials in frontotemporal lobar degeneration

David Irwin

Summary: Therapeutic development for familial forms of FTLD is rapidly growing, and there is a need for adequate clinical tools to measure treatment effect, as addressed by Peakman et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Article Clinical Neurology

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

Whitley W. Aamodt, Teresa Waligorska, Junchao Shen, Thomas F. Tropea, Andrew Siderowf, Daniel Weintraub, Murray Grossman, David Irwin, David A. Wolk, Sharon X. Xie, John Q. Trojanowski, Leslie M. Shaw, Alice S. Chen-Plotkin

Summary: The study found that neurofilament light chain protein (NfL) is associated with cognitive function in Parkinson's disease (PD) patients and can predict future cognitive decline. Plasma NfL was identified as a useful prognostic biomarker for PD, predicting the likelihood of PD patients converting to mild cognitive impairment or dementia.

MOVEMENT DISORDERS (2021)

Article Clinical Neurology

Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease

Sandhitsu R. Das, Xueying Lyu, Michael Tran Duong, Long Xie, Lauren McCollum, Robin Flores, Michael DiCalogero, David J. Irwin, Bradford C. Dickerson, Ilya M. Nasrallah, Paul A. Yushkevich, David A. Wolk

Summary: The study aimed to investigate the impact of Tau neurofibrillary tangles on neurodegeneration, and identified age and burden of white matter hyperintensity lesions as related modulatory factors. Data analysis showed that grouping individuals based on the relationship between Tau neurofibrillary tangles and neurodegeneration may help identify potential contributors to neurodegeneration.

ANNALS OF NEUROLOGY (2021)

Article Biochemical Research Methods

SpaGCN: Integrating gene expression, spatial location and histology to identify spatial domains and spatially variable genes by graph convolutional network

Jian Hu, Xiangjie Li, Kyle Coleman, Amelia Schroeder, Nan Ma, David J. Irwin, Edward B. Lee, Russell T. Shinohara, Mingyao Li

Summary: SpaGCN is a spatially resolved transcriptomics data analysis tool that uses graph convolutional networks to identify spatial domains and spatially variable genes. By integrating gene expression, spatial location, and histology, SpaGCN can detect genes with enriched spatial expression patterns and transferable to other datasets for studying spatial gene expression variation. SpaGCN is computationally fast, platform independent, and ideal for diverse SRT studies.

NATURE METHODS (2021)

Article Clinical Neurology

Plasma phosphorylated tau181 predicts cognitive and functional decline

Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw

Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Letter Clinical Neurology

Concomitant Alzheimer Disease Pathology in Parkinson Disease Dementia

Thomas F. Tropea, Isabela Albuja, Katheryn A. Q. Cousins, David J. Irwin, Edward B. Lee, Alice S. Chen-Plotkin

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies

Alexandra L. Young, Jacob W. Vogel, John L. Robinson, Corey T. McMillan, Rik Ossenkoppele, David A. Wolk, David J. Irwin, Lauren Elman, Murray Grossman, Virginia M. Y. Lee, Edward B. Lee, Oskar Hansson

Summary: Through data-driven disease progression modelling, a fine-grained empirical staging system for TAR DNA-binding protein-43 (TDP-43) proteinopathies has been established, which can accurately classify frontotemporal lobar degeneration due to TDP-43 (FTLD-TDP), amyotrophic lateral sclerosis (ALS) and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC). The study reveals substantial heterogeneity in the progression patterns of ALS and FTLD-TDP, and highlights the need for further investigation in larger cross-cohort studies.

BRAIN (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.

BRAIN (2023)

Review Clinical Neurology

Fluid and Biopsy Based Biomarkers in Parkinson's Disease

David G. Coughlin, David J. Irwin

Summary: Several advances have been made in fluid and tissue-based biomarkers for Parkinson's disease (PD) and other synucleinopathies in the last few years. Immunohistochemistry, immunofluorescence, and alpha-synuclein seeding amplification assays now offer a crucial advancement in identifying different species of alpha-synuclein in PD patients. Co-pathology of Alzheimer's disease (AD) is commonly found in PD and dementia with Lewy bodies (DLB), and biofluid biomarkers for tau and amyloid beta species can detect this co-pathology.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Review Medical Laboratory Technology

Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology

Ju Hee Kang, Magdalena Korecka, Edward B. Lee, Katheryn A. Q. Cousins, Thomas F. Tropea, Alice A. Chen-Plotkin, David J. Irwin, David Wolk, Magdalena Brylska, Yang Wan, Leslie M. Shaw

Summary: Development of validated biomarkers for early detection of Alzheimer's disease neuropathology is crucial for therapeutic trials. Although CSF and neuroimaging biomarkers have limitations, there is a growing focus on accelerating the development of blood-based AD biomarkers. The use of the AT(N) classification by CSF and imaging biomarkers provides a more objective diagnosis of AD. Blood-based AD biomarkers can be utilized as screening tools in therapeutic trials and clinical care.

CLINICAL CHEMISTRY (2023)

Article Clinical Neurology

Antemortem network analysis of spreading pathology in autopsy-confirmed frontotemporal degeneration

Min Chen, Sarah Burke, Christopher A. Olm, David J. Irwin, Lauren Massimo, Edward B. Lee, John Q. Trojanowski, James C. Gee, Murray Grossman

Summary: Chen et al. used graph-theoretic analyses of antemortem, multimodal MRIs to examine spreading pathology in structural networks of those with autopsy-confirmed frontotemporal lobar degeneration with either tau or transactional DNA binding protein of similar to 43 kDa inclusions. They report distinct patterns of long-range and short-range network degradation between the two pathologies, suggesting different mechanisms for their spread.

BRAIN COMMUNICATIONS (2023)

Article Clinical Neurology

Digital markers of motor speech impairments in spontaneous speech of patients with ALS-FTD spectrum disorders

Sanjana Shellikeri, Sunghye Cho, Sharon Ash, Carmen Gonzalez-Recober, Corey T. Mcmillan, Lauren Elman, Colin Quinn, Defne A. Amado, Michael Baer, David J. Irwin, Lauren Massimo, Christopher A. Olm, Mark Y. Liberman, Murray Grossman, Naomi Nevler

Summary: This study evaluated the effectiveness of automated digital speech measures in assessing bulbar motor impairments in patients with ALS-FTD spectrum disorders. The results showed that vowel measures derived from spontaneous speech were able to effectively assess bulbar dysfunction, with greater sensitivity and specificity compared to traditional assessments such as speaking rate.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Cell Biology

CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

Marta del Campo, Carel F. W. Peeters, Erik C. B. Johnson, Lisa Vermunt, Yanaika S. Hok-A-Hin, Mirrelijn van Nee, Alice Chen-Plotkin, David J. Irwin, William T. Hu, James J. Lah, Nicholas T. Seyfried, Eric B. Dammer, Gonzalo Herradon, Lieke H. Meeter, John van Swieten, Daniel Alcolea, Alberto Lleo, Allan I. Levey, Afina W. Lemstra, Yolande A. L. Pijnenburg, Pieter J. Visser, Betty M. Tijms, Wiesje M. van der Flier, Charlotte E. Teunissen

Summary: This study identifies specific dysregulated CSF proteins along the AD continuum, reflecting the multifactorial nature of disease progression. Some of these dysregulated proteins can be used as biomarkers for the diagnosis and clinical trials of AD.

NATURE AGING (2022)

Article Clinical Neurology

Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndrome

David G. Coughlin, H. Branch Coslett, Claire Peterson, Jeffrey S. Phillips, Corey McMillan, Edward B. Lee, John Q. Trojanowski, Murray Grossman, David J. Irwin

Summary: This study reported a case with overlapping clinical features of synucleinopathy and tauopathy, and through biomarker characterization and post-mortem sampling, showed lateralized tau and alpha-synuclein pathology suggesting possible synergistic relationships.

ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2022)

No Data Available